LWA
INO icon

Lowe Wealth Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Lowe Wealth Advisors’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-8
Closed -$1K – 271
2020
Q3 		$1K Hold
8
– – ﹤0.01% 247
2020
Q2 		$3K Sell
8
-25
-76% -$4.01K ﹤0.01% 210
2020
Q1 		$3K Buy
+33
New +$2.04K ﹤0.01% 211

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lowe Wealth Advisors's INO Position: Q4 2020 in Review

Lowe Wealth Advisors sold out of Inovio Pharmaceuticals (INO) in Q4 2020, closing a stake of 8 shares — an estimated $1K sold.

Lowe Wealth Advisors first reported a position in INO in Q1 2020 and held it in 3 quarters. The position peaked at $3K in Q2 2020. 227 funds tracked by Wall St. Rank hold INO as of Q4 2020.

  • Lowe Wealth Advisors reported no remaining Inovio Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Lowe Wealth Advisors sold 8 Inovio Pharmaceuticals shares in Q4 2020, an estimated $1K.
  • Lowe Wealth Advisors first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • Lowe Wealth Advisors's Inovio Pharmaceuticals position peaked at $3K in Q2 2020.
  • 227 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2020.

Based on Lowe Wealth Advisors's 13F filing for Q4 2020, filed 7 Jan 2021.